Research recruitment on high grade serous ovarian cancer patients and HRD testing

Opportunity details

Position type

Participant

Number of positions available

10

Organization

BC Cancer

Role overview

Researchers at BC Cancer are hoping to speak with advanced ovarian cancer patients about their experiences with HRD testing and PARP inhibitors. The findings from the study will be used to better understand patient experiences to inform future policy and research. The study is a one-to-one interview that will take no more than one hour, be held through telephone or virtually through Teams, and you will be provided with an honorarium for your time. If you are interested in participating, please follow the survey link at https://tinyurl.com/HRDStudy or contact Julia McKenna (jmckenna@bccrc.ca) from the research team for more information.

Required knowledge, experience, skills

We are looking to interview high grade serous, advanced ovarian cancer patients who have been offered the HRD (homologous recombination deficiency) test. If you were offered the test, this would have occurred prior to starting PARP inhibitor treatment (niraparib). To note, BRCA+ patients are not offered HRD testing.

Time commitment

The study is a one time, one-to-one interview that will take no more than one hour. The interview will be held through telephone or virtually through Microsoft Teams.

Location

Virtual interview

What can you expect from the research team?

If interested, you may follow the survey link at https://tinyurl.com/HRDStudy to assess your eligibility for the study. If eligible, you will be contacted by the research team to schedule a one time, 60 minute interview (virtual). Interviews will discuss participants' experiences with HRD testing and PARP inhibitors. All interviewees will be provided honorarium of $75 for their time. Additionally, you may contact Julia McKenna (jmckenna@bccrc.ca) from the research team with any questions or for more information.

Supports available to participate

Honoraria

Submission of interest deadline

September 30, 2025